Evening, Sunday September 17: | PEDIATRIC TUMORS; NOVEL THERAPEUTIC STRATEGIES |
Discussion leader : Peter Houghton, St Jude Children's Hospital, Memphis, TN
Carol Thiele, National Cancer Institute, Bethesda, MD
"Modulation of growth and differentiation in neuroblastomas"
Rupert Handgretinger, University of Tuebingen, Germany
"Immunological approaches to the treatment of neuroblastomas"
Morning, Monday September 18: | TUBULIN-INTERACTING AGENTS |
Discussion leader : Susan Horwitz, Albert Einstein College of Medicine, Bronx, NY
Robert Kramer, Bristol-Myers Squibb, Princeton, NJ
"Epothilones, a new class of tubulin interacting agents"
Gary Gorbsky, University of Oklahoma, Oklahoma City, OK
"The tension-dependent mitotic checkpoint"
Dario Altieri, Yale University School of Medicine, New Haven, CN
"Control of apoptosis and mitotic spindle checkpoint by survivin"
Evening, Monday September 18: | DNA TOPOISOMERASES |
Discussion leader : Andrzej Skladanowski, Technical University of Gdansk, Poland
Jamal Tazi, Institute of Molecular Genetics, CNRS, Montpellier, France
"Topoisomerase I as a transcriptional modulator"
Giuseppe Giaccone, Free University Hospital, Asterdam, The Netherlands
"New topoisomerase inhibitors in clinical development"
Morning, Tuesday September 19: | DRUG RESISTANCE |
Discussion leader : Susan Cole, Queen's University, Kingston, Canada
Anne Dantzig, Lilly Research Laboratories, Indianapolis, IN
"Modulation of multidrug resistance with the P-glycoprotein inhibitor, LY 335979"
Ze'ev Ronai, Ruttenberg Cancer Center, New York, NY
"Coordinated regulation of stress kinases by GSTp - implications for cell death"
Bernard Salles, Institute of Pharmacology and Structural Biology, CNRS, Toulouse, France
"DNA-dependent protein kinase activity and sensitivity to anticancer agents"
Evening, Tuesday September 19: | IMAGING IN CANCER DRUG DEVELOPMENT |
Discussion leader : Susan Arbuck, National Cancer Institute, Bethesda, MD
Paul Workman, CRC Centre for Cancer Therapeutics, Surrey, UK
"Molecular and functional imaging endpoints in trials of novel mechanisms-based agents"
Thomas Meade, California Institute of Technology, Pasadena, CA
"Noninvasive magnetic resonance imaging of cell signaling and gene expression"
Morning, Wednesday September 20: | TUMOR ANGIOGENESIS |
Discussion leader : Roy Bicknell, ICRF Institut of Molecular Medicine, Oxford, UK
Don Ogilvie, AstraXeneca, Macclesfield, UK
"Inhibition of VEGF signal transduction in cancer"
Elisabetta Dejana, Mario Negri Institute, Milan, Italy
"The role of junctional molecules in endothelial cell signaling and in the maintenance of vascular integrity"
Patrice Yeh, Aventis, Villejuif, France
"Antiangiogenic gene therapy"
Evening, Wednesday September 20: | ONCOGENE-DIRECTED THERAPY |
Discussion leader : Caroline Dive, University of Manchester, Manchester, UK
Elisabeth Buchdunger, Novartis Pharma, Basel, Switzerland
"STI571, an Abl tyrosine kinase inhibitor"
David Kirn, Onyx Pharmaceuticals, Richmond,CA
"Adenoviral mutants targeting p53-deficient tumor cells"
Morning, Thursday September 21: | CELLULAR ORGANIZATION AND TENSEGRITY |
Discussion leader : Jeffrey Nickerson, University of Massachusetts, Worchester, MA
Donald Ingber, Children's Hospital and Harvard Medical School, Boston MA
"Control of cell cycle progression by cell shape and cytoskeletal tension"
David Kwiatkowski, Brigham Women's Hospital, Boston, MA
"Cytoskeleton, gelsolin and cancer"
Peter Cook, University of Oxford, Oxford, UK
"Transcription factories and their relation to genome structure and function"
Evening, Thursday September 21 | Gala dinner |
Dinner Speaker : Joseph Bertino, Memorial Sloan-Kettering Cancer Center, New York, NY
|